Scancell Holdings (FRA:SCP) Total Current Assets : €19.62 Mil (As of Oct. 2023)

View and export this data going back to 2013. Start your Free Trial

What is Scancell Holdings Total Current Assets?

Total current assets includes Cash, Cash Equivalents, Marketable Securities, Total Receivables, Total Inventories, and Other Current Assets. Scancell Holdings's total current assets for the quarter that ended in Oct. 2023 was €19.62 Mil.

Scancell Holdings Total Current Assets Historical Data

The historical data trend for Scancell Holdings's Total Current Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Scancell Holdings Total Current Assets Chart

Scancell Holdings Annual Data

Trend

Apr14

Apr15

Apr16

Apr17

Apr18

Apr19

Apr20

Apr21

Apr22

Apr23

Total Current Assets

Get a 7-Day Free Trial

8.19

5.95

51.72

38.77

27.95

Scancell Holdings Semi-Annual Data
	Apr14	Oct14	Apr15	Oct15	Apr16	Oct16	Apr17	Oct17	Apr18	Oct18	Apr19	Oct19	Apr20	Oct20	Apr21	Oct21	Apr22	Oct22	Apr23	Oct23
Total Current Assets	Get a 7-Day Free Trial															45.38	38.77	37.29	27.95	19.62

Scancell Holdings Total Current Assets Calculation

Total Current Assets are the asset that can be converted to cash or used to pay current liabilities within 12 months.

Scancell Holdings's Total Current Assets for the fiscal year that ended in Apr. 2023 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	22.624	+	0.611	+	0	+	4.711
	=	27.95

Scancell Holdings's Total Current Assets for the quarter that ended in Oct. 2023 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	15.086	+	0.549	+	0	+	3.984
	=	19.62

Total Current Assets is linked to the Current Ratio, which is the result of dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations.

Total Current Assets is also linked to Working Capital, Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

Scancell Holdings (FRA:SCP) Total Current Assets Explanation

In Ben Graham's calculation of liquidation value, inventory is only considered worth half of its book value, and accounts receivable is considered worth 75% of its value. Therefore the liquidation value is lower than calculated from total current assets.

Scancell Holdings's Liquidation Value for the quarter that ended in Oct. 2023 is

	Liquidation value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	15.086	-	35.314	+	0.75 * 0.549	+	0.5 * 0
=	-19.82

Scancell Holdings Total Current Assets Related Terms

Thank you for viewing the detailed overview of Scancell Holdings's Total Current Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Scancell Holdings (FRA:SCP) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Scancell Holdings PLC (FRA:SCP) » Definitions » Total Current Assets

Comparable Companies

Traded in Other Exchanges

SCLP.GB:UK SCLP:UK

Address

Sanders Road, Unit 202, Bellhouse Building, Oxford Science Park, Oxford, GBR, OX4 4GD

Website

https://www.scancell.co.uk

Scancell Holdings PLC is engaged in the discovery and development of novel vaccines for the treatment of cancer. The company is exploiting the unrivalled potential of the immune system to seek out and destroy cancer using two proprietary immuno-oncology platforms: ImmunoBody and Moditope. Its potent innovative DNA-based ImmunoBody therapies generate ultra-high avidity T cell responses that target and eliminate cancerous tumors. Its Moditope platform technology overcomes the immune suppression induced by tumors themselves, allowing activated T cells to seek out and kill tumor cells that would otherwise be hidden from the immune system.

Scancell Holdings (FRA:SCP) Headlines

No Headlines